Renal Transplant Rejection Clinical Trial
Official title:
A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation
A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation
The commonest cause of renal transplant failure worldwide is rejection, a process whereby the recipient's immune system recognises the transplant kidney as foreign and attacks it. One common form of rejection is due to the recipient developing antibodies against their kidney transplant. Spleen tyrosine kinase is a molecule present in immune cells which is important in the process of antibody mediated damage. Fostamatinib is a drug which inhibits spleen tyrosine kinase. This clinical trial will recruit 10 patients who have a renal transplant and a diagnosis of antibody mediated rejection. Patients will be given Fostamatinib for 12 months and will undergo a renal biopsy at 6 months and at a 12 months in order to determine whether the histological signs of antibody mediated rejection have either improved or not progressed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03140514 -
Urine CXCL10 Chemokine Monitoring Post-renal Transplant
|
N/A | |
| Completed |
NCT02581436 -
Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR
|
N/A | |
| Active, not recruiting |
NCT02409940 -
To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients
|
Phase 1 | |
| Completed |
NCT02377193 -
Simulect Versus ATG in Sensitized Renal Transplant Patient
|
Phase 4 | |
| Completed |
NCT00771745 -
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
|
Phase 4 | |
| Not yet recruiting |
NCT05385432 -
Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies
|
Phase 3 | |
| Completed |
NCT01953120 -
Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
|
Phase 4 | |
| Terminated |
NCT01324934 -
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
|
Phase 3 | |
| Terminated |
NCT00983645 -
A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity
|
Phase 4 | |
| Active, not recruiting |
NCT04530630 -
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant
|
Phase 4 | |
| Recruiting |
NCT03707262 -
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
|
Phase 1/Phase 2 | |
| Completed |
NCT02006108 -
Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance
|
N/A | |
| Completed |
NCT02733029 -
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
|
Phase 2 | |
| Active, not recruiting |
NCT02057965 -
Mesenchymal Stromal Cell Therapy in Renal Recipients
|
Phase 2 | |
| Completed |
NCT00658073 -
Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
|
N/A | |
| Terminated |
NCT03646344 -
Heme Arginate in Transplantation Study
|
Phase 3 | |
| Completed |
NCT02866682 -
Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
|
Phase 4 | |
| Completed |
NCT02500251 -
Belimumab Impacting Transplant Eligibility
|
Phase 1/Phase 2 | |
| Completed |
NCT00866879 -
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
|
Phase 4 | |
| Active, not recruiting |
NCT03511560 -
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
|
Phase 4 |